Number | Name | Date | Kind |
---|---|---|---|
3701628 | Ashman | Oct 1972 | |
3948601 | Fraser et al. | Apr 1976 | |
4643876 | Jacobs et al. | Feb 1987 | |
5084239 | Moulton et al. | Jan 1992 | |
5115166 | Campbell et al. | May 1992 | |
5171525 | Jacob | Dec 1992 | |
5184046 | Campbell | Feb 1993 | |
5244629 | Caputo et al. | Sep 1993 | |
5413759 | Campbell et al. | May 1995 | |
5415368 | Jacob | Sep 1995 |
Number | Date | Country |
---|---|---|
474137 | Mar 1992 | EPX |
2253144 | Sep 1992 | GBX |
9215336 | Sep 1992 | WOX |
Entry |
---|
Premarket Notification (510(k)) of Johnson & Johnson, Oct. 1993, letter dated Dec. 11, 1991 to the FDA from Johnson & Johnson with Table of Contents; pp. 001 00002-00003, 002 00002-00013, 002 00018, 002 00022-00025, 002 00029-00042, 002 00046-00049, 002 00051-00052, 002 00056-00058, 002 00060, 002 00063-00064, 002 00069, 002 00075, and 002 00077-00078. |